Visfatin in human pregnancy: Maternal gestational diabetes vis-à-vis neonatal birthweight

Shali Mazaki-Tovi, Roberto Romero, Juan Pedro Kusanovic, Edi Vaisbuch, Offer Erez, Nandor Gabor Than, Tinnakorn Chaiworapongsa, Chia Ling Nhan-Chang, Percy Pacora, Francesca Gotsch, Lami Yeo, Sun Kwon Kim, Samuel S. Edwin, Sonia S. Hassan, Pooja Mittal

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Objective: Adipose tissue dysfunction, characterized by dysregulation of adipokines production and/or secretion, has been implicated in the pathophysiology of type-2 diabetes mellitus, a metabolic complication closely related to gestational diabetes mellitus (GDM). Recently, an association between circulating maternal visfatin, a novel adipokine with metabolic and immunoregulatory properties, and impaired glucose metabolism as well as with altered fetal growth, has been proposed. The aims of this study were to determine whether there is an association between maternal plasma visfatin concentration, GDM, and a large-for-gestational-age (LGA) newborn. Study design: This cross-sectional study, included pregnant women at term in the following groups: 1) normal pregnancy and an appropriate-for-gestational-age (AGA) neonate (n=54); 2) normal pregnancy and an LGA newborn (n=47); 3) GDM and an AGA newborn (n=56); 4) GDM and an LGA newborn (n=45). The study population was further stratified by first trimester BMI (<25 vs. ≥25 kg/m2). Maternal plasma visfatin concentration was determined by ELISA. Parametric and non-parametric statistics were used for analysis. Results: 1) Among women who delivered an AGA neonate, the median maternal plasma concentration of visfatin was higher in patients with GDM than in those with a normal pregnancy; 2) Among women with a normal pregnancy, those who delivered an LGA neonate had a higher median maternal plasma visfatin concentration than those who delivered an AGA neonate; 3) among patients with normal BMI, there were no significant differences in the median maternal plasma visfatin concentration between the four study groups; and 4) maternal GDM, as well as delivery of an LGA neonate were independently associated with a higher maternal plasma visfatin concentrations. Conclusion: The linkage between increased maternal circulating visfatin and the presence of GDM or delivery of an LGA neonate supports the hypothesis that perturbation of adipokines homeostasis may play a role in the pathophysiology of GDM or excess fetal growth.

Original languageEnglish
Pages (from-to)218-231
Number of pages14
JournalJournal of Perinatal Medicine
Issue number3
StatePublished - 1 May 2009
Externally publishedYes


  • Adipokine
  • Adipose tissue
  • Appropriate-for-gestational-age (AGA)
  • Gestational diabetes mellitus (GDM)
  • Large-for-gestational-age (LGA)
  • Pre-B cell colony-enhancing factor (PBEF)
  • Visfatin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology


Dive into the research topics of 'Visfatin in human pregnancy: Maternal gestational diabetes vis-à-vis neonatal birthweight'. Together they form a unique fingerprint.

Cite this